Truvada
E409694
Truvada is a prescription antiretroviral medication widely used both to treat HIV infection and as pre-exposure prophylaxis (PrEP) to help prevent HIV in high-risk individuals.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Truvada canonical | 1 |
| emtricitabine and tenofovir disoproxil fumarate | 1 |
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
HIV medication
ⓘ
antiretroviral medication ⓘ brand-name drug ⓘ fixed-dose combination drug ⓘ |
| approvedBy |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| ATCCode | J05AR02 ⓘ |
| boxedWarning |
risk of acute exacerbations of hepatitis B after discontinuation
ⓘ
risk of lactic acidosis and severe hepatomegaly with steatosis ⓘ |
| commonSideEffect |
diarrhea
ⓘ
headache ⓘ nausea ⓘ |
| containsDoseStrength |
emtricitabine 200 mg
ⓘ
tenofovir disoproxil fumarate 300 mg ⓘ |
| contraindication | severe renal impairment ⓘ |
| developer |
Gilead Sciences (board member)
ⓘ
surface form:
Gilead Sciences
|
| dosageForm | tablet ⓘ |
| drugClass |
nucleoside reverse transcriptase inhibitor
ⓘ
nucleotide reverse transcriptase inhibitor ⓘ |
| FDAApprovalIndication |
pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection
ⓘ
treatment of HIV-1 infection in combination with other antiretrovirals ⓘ |
| FDAApprovalYear | 2004 ⓘ |
| hasActiveIngredient |
emtricitabine
ⓘ
tenofovir disoproxil fumarate ⓘ |
| hasGenericName |
Truvada
self-linksurface differs
ⓘ
surface form:
emtricitabine and tenofovir disoproxil fumarate
|
| hasPatentHolder |
Gilead Sciences (board member)
ⓘ
surface form:
Gilead Sciences
|
| indication |
post-exposure prophylaxis for HIV (off-label in some settings)
ⓘ
pre-exposure prophylaxis for HIV-1 (PrEP) ⓘ treatment of HIV-1 infection ⓘ |
| isGenericAvailable | true ⓘ |
| isNotEffectiveAgainst | established HIV infection when used alone ⓘ |
| isOnWHOEML | yes ⓘ |
| isUsedWith | other antiretroviral agents ⓘ |
| legalStatusEU | prescription-only ⓘ |
| legalStatusUS | prescription-only ⓘ |
| marketingAuthorizationHolder |
Gilead Sciences (board member)
ⓘ
surface form:
Gilead Sciences
|
| pregnancyCategoryUS | B (historical classification) ⓘ |
| prevents | sexual transmission of HIV-1 when used as PrEP with adherence ⓘ |
| requiresCombinationForTreatment | yes ⓘ |
| requiresMonitoring |
HIV status before and during PrEP
ⓘ
renal function ⓘ |
| routeOfAdministration | oral ⓘ |
| seriousSideEffect |
decreased bone mineral density
ⓘ
renal impairment ⓘ |
| takenFrequency | once daily ⓘ |
| targets |
HIV-1
ⓘ
surface form:
HIV-1 reverse transcriptase
|
| usedForPopulation |
adolescents at high risk of HIV infection (meeting weight and other criteria)
ⓘ
adults at high risk of HIV infection ⓘ |
| usedInProgram | HIV prevention programs worldwide ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Gilead Sciences
this entity surface form:
emtricitabine and tenofovir disoproxil fumarate